While the top- and bottom-line numbers for NeoGenomics (NEO) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Related Keywords
, Key Company Metrics For Neogenomics , Clinical Services , Zacks Investment Research , Gross Clinical Services , Zacks Consensus Estimate , Wall Street , Key Company Metrics , Zacks Rank , Zacks Investment , Neogenomics , All Street Analysts , Eported Revenue ,
comparemela.com © 2020. All Rights Reserved.